GLICK, GARY,GHOSH, SHOMIR,ROUSH, WILLIAM R.,OLHAVA, EDWARD JAMES
申请号：
CA3021349
公开号：
CA3021349A1
申请日:
2017.04.19
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which a decrease in NLRP3 activity (e.g., a condition, disease or disorder associated with repressed or impaired NLRP3 signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.
